Biotech·NewAuction live· 1d 12h

GLP-Tweaks: stabilized GLP-1 analogues via NCAA backbone substitution

Promise79initial
Activation threshold37%
$220of $600

About

GLP-1 analogues lose potency to DPP-4 cleavage at the N-terminal His-Ala bond. We're testing whether NCAA substitution at position 2 gives a better serum-half-life-to-binding-penalty trade-off than the standard lipid-conjugation route. Pre-registered milestones, third-party assay vendor, all attestations signed.

Researcher

Amelia W.Verified researcher

Med-chem researcher focused on stabilized peptide therapeutics. Five years at a GLP-1-adjacent pharma program.

Prior ventures

0

Milestones

  1. 01Synthesize 6-analogue NCAA panel

    Synthesize and HPLC-purify six GLP-1 analogues with NCAA substitution at position 2, ≥95% purity.

    Pending
    Deadline: in 21dTranche: $1.2KOutputs:Synthesis reportHPLC tracesMass spec
  2. 02Plasma-stability assay (DPP-4 + serum)

    Quantify half-life vs native GLP-1 across both DPP-4 and pooled human serum, n=3.

    Pending
    Deadline: in 8wTranche: $1.2KOutputs:Stability datasetAssay protocol
  3. 03In-vitro receptor binding (GLP-1R)

    Measure receptor binding affinity for all six analogues; report Ki vs native.

    Pending
    Deadline: in 13wTranche: $1.2KOutputs:Binding datasetLab report
  4. 04Mouse PK pilot for top analogue

    Single-dose PK study (n=4) for the best stability/binding analogue.

    Pending
    Deadline: in 21wTranche: $2.0KOutputs:PK datasetCRO reportPreprint draft

Connected sources

Anchor literature

Agent rules

Activates at$600 pool
Monthly allowance$50
Auto-liquidateProgress < 30 for 30d
Auto-pivot on disputesON